It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Classic Hodgkin lymphoma (cHL) is characterized by a rich immune microenvironment as the main tumor component. It involves a broad range of cell populations, which are largely unexplored, even though they are known to be essential for growth and survival of Hodgkin and Reed–Sternberg cells. We profiled the gene expression of 25 FFPE cHL samples using NanoString technology and resolved their microenvironment compositions using cell-deconvolution tools, thereby generating patient-specific signatures. The results confirm individual immune fingerprints and recognize multiple clusters enriched in refractory patients, highlighting the relevance of: (1) the composition of immune cells and their functional status, including myeloid cell populations (M1-like, M2-like, plasmacytoid dendritic cells, myeloid-derived suppressor cells, etc.), CD4-positive T cells (exhausted, regulatory, Th17, etc.), cytotoxic CD8 T and natural killer cells; (2) the balance between inflammatory signatures (such as IL6, TNF, IFN-γ/TGF-β) and MHC-I/MHC-II molecules; and (3) several cells, pathways and genes related to the stroma and extracellular matrix remodeling. A validation model combining relevant immune and stromal signatures identifies patients with unfavorable outcomes, producing the same results in an independent cHL series. Our results reveal the heterogeneity of immune responses among patients, confirm previous findings, and identify new functional phenotypes of prognostic and predictive utility.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Fundación MD Anderson International España. Madrid, Translational Research, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543)
2 Fundación MD Anderson International España. Madrid, Translational Research, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543); MD Anderson Cancer Center Madrid, Pathology Department, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543)
3 Hospital Universitario Ramón y Cajal, Pathology Department, Madrid, Spain (GRID:grid.411347.4) (ISNI:0000 0000 9248 5770)
4 IIS Hospital Universitario Fundación Jiménez Díaz, Pathology Department, Madrid, Spain (GRID:grid.419651.e) (ISNI:0000 0000 9538 1950); ISCIII, Center for Biomedical Network Research on Cancer (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
5 MD Anderson Cancer Center Madrid, Hematology Department, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543)
6 Fundación MD Anderson International España. Madrid, Translational Research, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543); MD Anderson Cancer Center Madrid, Pathology Department, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543); ISCIII, Center for Biomedical Network Research on Cancer (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)